Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UNI-DUR vs KALEXATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
200-400 mg orally every 12 hours; maximum 800 mg daily.
10 mg orally once daily.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
95% bound to albumin.
60-70% primarily to albumin
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
1.2-1.6 L/kg; indicates extensive extravascular distribution
Oral: 85-95% (immediate-release); 70-80% (extended-release).
Oral: 85-95%
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
Not approved for pediatric use.
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
No specific dose adjustment; monitor renal function.
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UNI-DUR vs KALEXATE, answered by our medical review team.
UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UNI-DUR and KALEXATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. The standard adult dose of KALEXATE is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UNI-DUR and KALEXATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.